Marker Therapeutics, Inc. Common Stock MRKR
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $10.00 (+769.6% upside)
Key Stats
- Today's Range
- $1.15 – $1.22
- 50-Day Range
- $1.05 – $1.60
- 52-Week Range
- $0.81 – $2.46
- Volume
- 31K shs
- Average Volume
- 75K shs
- Market Cap
- $19.17 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 8.47%
- Days to Cover
- 7.76
About Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Related Stocks
Compare head-to-head: MRKR vs LLY·MRKR vs JNJ·MRKR vs ABBV·MRKR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.